NASDAQ NMS - GLOBAL MARKET · ALLR
-3.36% · -$0.0460 · Vol 56.6K
Market closed · last close 4:00 PM ET · price as of 19:32:44 ET
Allarity Therapeutics Inc

Allarity Therapeutics Inc

Biotechnology
$1.32
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
ALLR
Allarity Therapeutics Inc
Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

66/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALLR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALLR catalysts
About Allarity Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
8
Country
US

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.39
Day high
$1.39
Day low
$1.31
Previous close
$1.37
52W high
$1.97
-32.79% from high
52W low
$0.8100
44% of range
Market cap
$21.8M
EPS
$-0.2100
Beta
1.74
Shares out
15.9M
Volume
56.6K
0.64× rel vol
Avg volume
88.9K
VWAP
$1.35
Price history computed in-house
1W
-7.41%
1M
+11.26%
3M
-11.14%
1Y
+45.48%
YTD
+22.59%
SMA 50 $1.31 · above
SMA 200 $1.23 · above
52W position 44%

ALLR overview

Veridion Score
66
Daily close · 2026-08-17
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALLR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALLR Form 4 filings
Public disclosures

Congress activity in ALLR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALLR in the cached public ledger.

Federal contracts

ALLR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALLR in this window.
Lobbying spend

ALLR lobbying filings, year to date.

Registered lobbying filings matched to Allarity Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALLR in this window.
Loading news for ALLR
Analyst ratings
Sovereign unlock shows live analyst consensus for ALLR.
Options
Sovereign unlock shows live options positioning for ALLR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.